dupilumab
regeneron,sanofi
['dupixent', 'prurigo nodularis', 'dupilumab']
dupixent (dupilumab) late-breaking phase 3 data at eadv 2022 showed significant improvements in signs and symptoms of prurigo nodularis #pharmanews #clinicalresearchnews #biotechnews #lifesciencesnews #medicalnews #healthcarenews #pharmiwebnews 
News from across the pharmaceutical and biotech industry from PharmiWeb https://t.co/ea1b58MZYg